Back to Search
Start Over
Vomiting in children and adolescents receiving intravenous pegaspargase: a retrospective study.
- Source :
-
Pediatric Hematology & Oncology . Aug2024, Vol. 41 Issue 5, p376-381. 6p. - Publication Year :
- 2024
-
Abstract
- Due to an evidence gap, the emetogenicity of intravenous (IV) pegaspargase was unable to be included in the clinical practice guideline classifying chemotherapy emetogenicity in pediatric patients. This single-center, retrospective chart review describes the proportion of pediatric patients who did not vomit during the acute phase (complete response; CR) after receiving IV pegaspargase and provides an emetogenicity classification using a preexisting framework. Of 44 patients who received IV pegaspargase between 2011 and 2020, 13 received a serotonin receptor antagonist plus dexamethasone or palonosetron alone and all experienced a CR. We, therefore, recommend classifying IV pegaspargase as moderately emetogenic. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 08880018
- Volume :
- 41
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Pediatric Hematology & Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 178943653
- Full Text :
- https://doi.org/10.1080/08880018.2024.2311886